Evidence map›Paper›PMID 41045195›Full record

ReviewAdvanced healthcare materials2026

Harnessing Next-Generation 3D Cancer Models to Elucidate Tumor-Microbiome Crosstalk.

Marina Green Buzhor, Giuseppe Longobardi, Or Kandli, Anne Krinsky, Opal Avramoff, Anshika Katyal, Koren Salomon, Adan Miari, Dana Venkert, Tania T Barnatan and 3 more

Abstract readReview
In one paragraph

Review in Advanced healthcare materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Marina Green BuzhorDepartment of Physiology and Pharmacology, Gray School of Medical Sciences, Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, 6997801, Israel.ORCID 0009-0001-7913-3513
Giuseppe LongobardiDepartment of Physiology and Pharmacology, Gray School of Medical Sciences, Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, 6997801, Israel.ORCID 0000-0003-4617-5546
Or KandliDepartment of Physiology and Pharmacology, Gray School of Medical Sciences, Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, 6997801, Israel.
Anne KrinskyDepartment of Physiology and Pharmacology, Gray School of Medical Sciences, Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, 6997801, Israel.ORCID 0009-0005-5421-9862
Opal AvramoffDepartment of Physiology and Pharmacology, Gray School of Medical Sciences, Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, 6997801, Israel.
Anshika KatyalDepartment of Physiology and Pharmacology, Gray School of Medical Sciences, Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, 6997801, Israel.ORCID 0009-0003-1910-4424
Koren SalomonDepartment of Physiology and Pharmacology, Gray School of Medical Sciences, Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, 6997801, Israel.ORCID 0009-0008-2300-369X
Adan MiariDepartment of Physiology and Pharmacology, Gray School of Medical Sciences, Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, 6997801, Israel.ORCID 0009-0007-7308-0573
Dana VenkertDepartment of Physiology and Pharmacology, Gray School of Medical Sciences, Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, 6997801, Israel.ORCID 0009-0000-2919-6308
Tania T BarnatanDepartment of Physiology and Pharmacology, Gray School of Medical Sciences, Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, 6997801, Israel.ORCID 0000-0002-4409-6687
América García AlvaradoDepartment of Physiology and Pharmacology, Gray School of Medical Sciences, Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, 6997801, Israel.ORCID 0009-0000-0132-8110
Shahar GreenbergDepartment of Physiology and Pharmacology, Gray School of Medical Sciences, Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, 6997801, Israel.
Ronit Satchi-FainaroDepartment of Physiology and Pharmacology, Gray School of Medical Sciences, Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, 6997801, Israel.ORCID 0000-0002-7360-7837

Funding

ERC PoC 101113390ERC PoC 3DCanPredictERC PoC 862580ERC PoC ImmuNovationEuropean Research Council (ERC) Advanced 3DBrainStromEuropean Research Council (ERC) Advanced 835227Israel Cancer Research Fund (ICRF) PROF-18-602Israel Science Foundation ISF 3706/24"La Caixa" Foundation LCF/PR/HR19/52 160 021"La Caixa" Foundation LCF/PR/HR22/52 420 016"La Caixa" Foundation LCF/PR/HR24/00968Morris Kahn FoundationThe European Innovation Council (EIC) 101214384The European Innovation Council (EIC) TIMNano
6 · The paper itself

Abstract

The tumor microenvironment (TME) is a complex and dynamic ecosystem increasingly recognized for its interplay with the microbiome. In colorectal, breast, lung, liver, and brain cancers, bacterial communities and their metabolites are shown to influence tumor progression, immune responses, and therapeutic outcomes. To study these interactions in physiologically relevant contexts, advanced 3D in vitro models have emerged, including spheroids, organoids, microfluidic organ-on-a-chip platforms, and 3D-bioprinted constructs. These systems provide spatial organization, mechanical cues, and co-culture capabilities that facilitate investigation of host-microbiome-tumor cross-talk. Incorporation of live bacteria, their metabolites, and immune components into these platforms has yielded new insights into how the microbiome shapes cancer behavior, inflammation, and drug resistance. This review outlines recent advances in 3D model development for studying tumor-microbiome interactions, highlighting organ-specific applications, extracellular matrix-mimicking hydrogels, and biofabrication strategies. It also addresses key challenges, including maintaining microbiome viability, modeling temporal dynamics, and integrating immune complexity. Overcoming these limitations requires interdisciplinary approaches that merge bioengineering, microbiology, and oncology. Evolving 3D platforms offer powerful tools for microbiome-informed cancer modeling and hold significant promise for advancing therapeutic screening and precision oncology.

Indexed as

MicrobiotaModels, BiologicalNeoplasmsTumor MicroenvironmentAnimalsHumansHydrogelsOrganoidsHydrogels3D cancer modelsco‐culture systemsmicrobiometumor‐microbiome interactionstumor microenvironment

Identifiers

PMID41045195
PMCPMC12790331

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.